Lentiviral vector mediated thymidine kinase expression in pluripotent stem cells enables removal of tumorigenic cells.
Embryonic stem cells (ES) and induced pluripotent stem (iPS) cells represent promising tools for cell-based therapies and regenerative medicine. Nevertheless, implantation of ES cell derived differentiated cells holds the risk of teratoma formation due to residual undifferentiated cells. In order to tackle this problem, we used pluripotent stem cells consisting of ES and iPS cells of mouse genetically modified by lentiviral vectors (LVs) carrying herpes simplex virus thymidine kinase (HSV-TK) under the control of different promoters of pluripotency genes. Cells expressing TK in turn are eliminated upon administration of the prodrug ganciclovir (GCV). Our aim was to study the conditions required for a safe mechanism to clear residual undifferentiated cells but using low MOIs of lentiviruses to reduce the risk of insertional mutagenesis. Our in vitro data demonstrated that TK expression in pluripotent stem cells upon treatment with GCV led to elimination of undifferentiated cells. However, introduction of hygromycin resistance in the LV transduced ES cells followed by pre-selection with hygromycin and GCV treatment was required to abolish undifferentiated cells. Most importantly, transplantation of pre-selected ES cells that had been transduced with low MOI LV in mice resulted in no teratoma development after GCV treatment in vivo. Taken together, our data show that pre-selection of ES cells prior to in vivo application is necessary if vector integration events are minimized. The study presented here gives rise to safer use of pluripotent stem cells as promising cell sources in regenerative medicine in the future.
Institute of Pharmacology and Toxicology, University of Bonn, Bonn, Germany.
Tiong-Ti
TT
Lim
Caroline
C
Geisen
Michael
M
Hesse
Bernd K
BK
Fleischmann
Katrin
K
Zimmermann
Alexander
A
Pfeifer
D000818:Animals; D024201:Bystander Effect; D002460:Cell Line; D004195:Disease Models, Animal; D053595:Embryonic Stem Cells / Q000378:metabolism; D015774:Ganciclovir / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D023061:Gene Order; D041722:Genes, Transgenic, Suicide; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics*; D016086:Lentivirus / Q000235:genetics*; D051379:Mice; D039904:Pluripotent Stem Cells / Q000378:metabolism* / Q000637:transplantation; D011355:Prodrugs / Q000494:pharmacology; D011401:Promoter Regions, Genetic; D018139:Simplexvirus / Q000201:enzymology; D033581:Stem Cell Transplantation; D013724:Teratoma / Q000235:genetics / Q000473:pathology / Q000628:therapy; D013937:Thymidine Kinase / Q000235:genetics* / Q000378:metabolism*; D014161:Transduction, Genetic
D011355:Prodrugs; D013937:Thymidine Kinase; D015774:Ganciclovir